secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-07-14T23:59:59+00:00
Accession:  0001493152-23-024532
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte amends CEO employment agreement; removes 800,000-share performance option grant
--------------------------------------------------------------------------------

- CEO Joshua Riggs' 800,000-share performance option grant eliminated under amendment dated July 13, 2023.
- Company may grant new performance-based options if shareholders approve plan amendment to remove annual individual limit.
- Amendment also modifies equity vesting acceleration provisions for time-based awards in certain termination scenarios.
- Base salary remains $360,000; target bonus unchanged at 50% of base salary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223024532/0001493152-23-024532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223024532/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-024532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer